Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock

Core Insights - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is recognized as a leading biotechnology company focusing on weight loss drugs that help users maintain lean muscle mass while losing weight [1] - The company's stock has seen a year-to-date increase of 16.32%, with a notable rise of 10.6% since being highlighted by Jim Cramer in March 2025 [1] - Regeneron reported third-quarter earnings of $3.75 billion in revenue and $11.83 in profit per share, surpassing analyst expectations [1] Stock Performance - The stock closed 11.8% higher on October 28th following the earnings report [1] - Year-to-date, shares are down by 4.9%, with a significant dip occurring between January 9th and 16th [1] - Bank of America upgraded Regeneron's rating from Underperform to Buy and raised the price target from $627 to $860 [1] Analyst Commentary - Jim Cramer expressed confidence in Regeneron, stating it is performing better than perceived and recommended ownership of the stock [1]